Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPhysiomics Regulatory News (PYC)

Share Price Information for Physiomics (PYC)

Share Price is delayed by 15 minutes
Get Live Data
0.625    -0.025 (-3.85%)
Bid:
0.60
Ask:
0.65
Spread: 0.05 (8.333%)
Market Cap: £2.83m
PYC Live PriceLast checked at - London Stock Exchange

Intraday Physiomics Share Chart

Director/PDMR Shareholding

6 Apr 2018 14:40

RNS Number : 1567K
Physiomics PLC
06 April 2018
Β 

Physiomics plc

("Physiomics") or ("the Company")

Β 

Director Dealing

Β 

The Company announces that it received notice today that Dr Chassagnole (COO) transferred paper share certificates of 121,522 shares and 265,111 shares to his nominee account 'Interactive Investor Services Nominees Limited'.

Β 

Following the transfer of shares, Dr Chassagnole's beneficial holding remains unchanged at 417,008 ordinary shares (equivalent to 0.71% of the currently issued share capital).

Β 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

Β 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Christophe Chassagnole

2

Reason for the notification

a)

Position/status

Director, COO

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Physiomics plc

b)

LEI

213800A71DSZ6ABMTQ91

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Β 

Β 

Identification code

Transfer of securities held in paper share certificates to nominee account 'Interactive Investor Services Nominees Limited'

Β 

GB00BDR6W943

b)

Nature of the transaction

Trans

c)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

N/A

121,522

265,111

d)

Aggregated information

- Aggregated volume

- Price

Β 

386,663

N/A

e)

Date of the transaction

05/04/2018

f)

Place of the transaction

XOFF

Β 

Β 

Enquiries:

Β 

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

Β 

WH Ireland Limited (nomad)

Katy Mitchell, James Sinclair-Ford

+44 (0) 161 832 2174

Β 

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Β 

Β 

The information contained within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulation (EU) No. 596/2014.

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
DSHIFMJTMBJMBLP
Date   Source Headline
29th Apr 20154:27 pmRNSHolding(s) in Company
22nd Apr 20157:00 amRNSVirtual Tumour platform - AACR Annual Meeting 2015
26th Mar 20157:00 amRNSIssue of Options
17th Mar 20157:00 amRNSHalf Yearly Report
12th Mar 20157:00 amRNSIssue of Equity
6th Mar 20151:40 pmRNSHolding(s) in Company
4th Mar 201511:56 amRNSHolding(s) in Company
3rd Mar 201512:57 pmRNSFirst contract for clinical version of Virtu
20th Feb 201512:34 pmRNSHolding(s) in Company
2nd Feb 20157:00 amRNSTermination of Equity Swap Agreement
15th Dec 20141:08 pmRNSResult of AGM
12th Nov 201410:24 amRNSFinal Results
4th Nov 20147:00 amRNSDisclosure of Large Pharma partner Merck & Co
27th Oct 201410:07 amRNSProject extension with global pharma company
13th Oct 20144:43 pmRNSHolding(s) in Company
7th Oct 20149:35 amRNSCardiotox Platform Launch
29th Aug 20142:47 pmRNSHolding(s) in Company
14th Aug 20141:10 pmRNSNew deal with global pharma
24th Jul 201412:59 pmRNSIssue of Equity
26th Jun 20147:57 amRNSHolding(s) in Company
12th Jun 20147:00 amRNSAnticipated new collaboration with Diatech
20th May 20149:47 amRNSHolding(s) in Company
10th Apr 20147:00 amRNSSecond validation of Virtual Tumour Clinical
14th Feb 20147:00 amRNSHalf Yearly Report
30th Jan 20144:41 pmRNSIssue of Equity - Replacement
30th Jan 20143:02 pmRNSIssue of Equity
16th Jan 20147:20 amRNSDundee University Collaboration
17th Dec 20132:07 pmRNSResult of AGM
4th Dec 201310:47 amRNSVirtual Tumour Proposal
28th Nov 20131:24 pmRNSDrugCARD launch
15th Nov 20137:00 amRNSFinal Results
11th Nov 20137:00 amRNSUniversity of Oxford Collaboration
4th Nov 20137:00 amRNSUpdate on the Virtual Tumour Clinical platform
10th Oct 201310:30 amRNSDrawdown pursuant to SEDA Arrngmnt/Issue of Equity
7th Oct 20138:32 amRNSPhysiomics gains new speciality pharma customer
1st Oct 201311:49 amRNSPhysiomics gains first large pharma customer
16th Sep 20137:00 amRNSPhysiomics to present cardiac toxicity platform
26th Jul 20131:30 pmRNSIssue of Equity
1st Jul 20137:00 amRNSAdditional SEDA Drawdown
24th Jun 20137:00 amRNSWins Poster Award
20th Jun 20134:28 pmRNSAward of Grant
11th Jun 20137:00 amRNSPopulation Approach Group Europe
6th Jun 20137:00 amRNSVirtual Tumour Clinical Contract
8th Apr 20138:03 amRNSPhysiomics to present new developments
25th Mar 20137:00 amRNSPhysiomics to provide cardiac toxicity modelling
18th Mar 20137:00 amRNSNew clinical PK/PD modelling service
13th Feb 201311:10 amRNSIssue of Options
11th Feb 20133:23 pmRNSDirector Declaration
8th Feb 20137:00 amRNSHalf Yearly Report
22nd Jan 20137:00 amRNSSEDA Arrangement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.